Agomelatine

NERVOUS SYSTEM

Key facts

Agomelatine is a drug catalogued in DrugCentral. It was first approved by the EMA in 2009. DrugCentral lists 7 molecular targets, including MTNR1A, MTNR1A|MTNR1B and MTNR1B. Recorded indications include Major depressive disorder.

• Molecular targets: MTNR1A, MTNR1A|MTNR1B, MTNR1B and Melatonin receptor (7 listed in DrugCentral).
• Indications: Major depressive disorder.
• ATC code: N06AX22 (Other antidepressants).
• Molecular formula: C15H17NO2; molecular weight 243.31 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Major depressive disorder

Mechanism & targets

Molecular targets (7)

Target	Gene	Action	Activity
Melatonin receptor type 1A	MTNR1A	agonist	Ki 10.22
Melatonin receptor	MTNR1A|MTNR1B	unknown	Ki 10.00
Melatonin receptor type 1B	MTNR1B	agonist	Ki 10.00
Melatonin receptor	—	unknown	Ki 9.28
5-hydroxytryptamine receptor 2B	HTR2B	antagonist	Ki 6.60
5-hydroxytryptamine receptor 2C	HTR2C	antagonist	Ki 6.20
5-hydroxytryptamine receptor 2A	HTR2A	antagonist	Ki 5.40

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2009-02-19	EMA	—	Les Laboratoires Servier

ATC classification

ATC code	Therapeutic hierarchy
N06AX22	NERVOUS SYSTEM › PSYCHOANALEPTICS › ANTIDEPRESSANTS › Other antidepressants

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Amaurosis fugax	772.3
Ocular discomfort	690.5
Haemorrhagic stroke	651.3
Head discomfort	638.4
Urinary tract disorder	629.2
Blindness	499.6
Generalised oedema	487.3
Altered state of consciousness	485.3
Eye pain	464.8
Haematemesis	463.9
Presyncope	411.7
Diplopia	410.9

Chemical structure

• Molecular formula: C₁₅H₁₇NO₂
• Molecular weight: 243.31 g/mol
• CAS number: 138112-76-2
• InChIKey: YJYPHIXNFHFHND-UHFFFAOYSA-N
• PubChem CID: 82148

COC1=CC2=C(C=CC=C2CCNC(C)=O)C=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Agomelatine used for?

DrugCentral lists the following indications for Agomelatine: Major depressive disorder.

How does Agomelatine work?

Its molecular targets in DrugCentral include MTNR1A (agonist), MTNR1A|MTNR1B, MTNR1B (agonist) and Melatonin receptor.

When was Agomelatine first approved?

Agomelatine was first approved by the EMA in 2009.

What is the chemical formula of Agomelatine?

Agomelatine has the molecular formula C15H17NO2 and a molecular weight of 243.31 g/mol.

Sources

• DrugCentral drug card 99 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL10878 — compound record and bioactivity
• PubChem CID 82148 — chemical identifiers
• DrugBank DB06594 — drug record
• FDA UNII 137R1N49AD — substance identity
• UniProt P48039 (MTNR1A) — target protein
• UniProt P49286 (MTNR1B) — target protein
• UniProt P41595 (HTR2B) — target protein
• UniProt P28335 (HTR2C) — target protein
• UniProt P28223 (HTR2A) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.